AQR Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.16M | Sell |
230,577
-146,867
| -39% | -$1.38M | ﹤0.01% | 1728 |
|
|
2025
Q1 | $4.64M | Buy |
377,444
+312,231
| +479% | +$3.84M | ﹤0.01% | 1159 |
|
|
2024
Q4 | $862K | Buy |
65,213
+39,794
| +157% | +$526K | ﹤0.01% | 1964 |
|
|
2024
Q3 | $489K | Sell |
25,419
-1,854
| -7% | -$35.7K | ﹤0.01% | 2178 |
|
|
2024
Q2 | $560K | Sell |
27,273
-25,943
| -49% | -$533K | ﹤0.01% | 2007 |
|
|
2024
Q1 | $1.27M | Buy |
53,216
+17,314
| +48% | +$412K | ﹤0.01% | 1596 |
|
|
2023
Q4 | $776K | Buy |
35,902
+11,330
| +46% | +$245K | ﹤0.01% | 1699 |
|
|
2023
Q3 | $357K | Buy |
24,572
+3,034
| +14% | +$44.1K | ﹤0.01% | 1967 |
|
|
2023
Q2 | $451K | Sell |
21,538
-1,690
| -7% | -$35.4K | ﹤0.01% | 1821 |
|
|
2023
Q1 | $491K | Sell |
23,228
-1,947
| -8% | -$41.1K | ﹤0.01% | 1782 |
|
|
2022
Q4 | $641K | Buy |
25,175
+3,246
| +15% | +$82.6K | ﹤0.01% | 1722 |
|
|
2022
Q3 | $527K | Sell |
21,929
-13,429
| -38% | -$323K | ﹤0.01% | 1759 |
|
|
2022
Q2 | $680K | Buy |
35,358
+11,607
| +49% | +$223K | ﹤0.01% | 1570 |
|
|
2022
Q1 | $413K | Buy |
+23,751
| New | +$413K | ﹤0.01% | 1884 |
|
|
2021
Q2 | – | Sell |
-18,680
| Closed | -$418K | – | 2291 |
|
|
2021
Q1 | $418K | Sell |
18,680
-11,283
| -38% | -$252K | ﹤0.01% | 1901 |
|
|
2020
Q4 | $666K | Sell |
29,963
-12,972
| -30% | -$288K | ﹤0.01% | 1682 |
|
|
2020
Q3 | $634K | Sell |
42,935
-1,873
| -4% | -$27.7K | ﹤0.01% | 1630 |
|
|
2020
Q2 | $664K | Buy |
44,808
+34,079
| +318% | +$505K | ﹤0.01% | 1644 |
|
|
2020
Q1 | $118K | Buy |
+10,729
| New | +$118K | ﹤0.01% | 1943 |
|
|
2019
Q2 | – | Sell |
-14,117
| Closed | -$74K | – | 2171 |
|
|
2019
Q1 | $74K | Buy |
+14,117
| New | +$74K | ﹤0.01% | 2142 |
|
|
2018
Q1 | – | Sell |
-26,068
| Closed | -$228K | – | 2272 |
|
|
2017
Q4 | $228K | Sell |
26,068
-7,121
| -21% | -$62.3K | ﹤0.01% | 2123 |
|
|
2017
Q3 | $388K | Buy |
+33,189
| New | +$388K | ﹤0.01% | 2013 |
|